Efficacy of GLP-1 Receptor Agonists (E.G., Semaglutide) In Non- Diabetic Obesity Management

Abstract

The problem of obesity has now been recognized as one of the most important problems in the world. There has
been an alarming rise in the incidence of obesity, which has also caused morbidity and mortality. Various health
hazards of obesity include cardiovascular disease, metabolic disease, and cancer. It is accepted that lifestyle
modification is an important factor in the management of obesity. However, it is difficult to achieve long-term
management of obesity. This has necessitated the pharmacological management of obesity.
Currently, there are a number of persons who understand that there is a potential for a new way of treating obesity
by utilizing glucagon-like peptide-1 receptor agonists. Although most of these medications were developed for
the purpose of treating type 2 diabetes, they have also shown that they can be used for the purpose of treating
obesity. It is believed that semaglutide is the most potent of all the GLP-1 modulators, as it not only slows down
the rate of gastric emptying but also suppresses appetite and induces society
Substantial weight loss in body weight, body mass index, and waist circumference has also been reported in
nondiabetic patients in recent clinical trials of semaglutide treatment versus placebo.Aside from weight loss, there
are reports that improvements in other aspects of cardiometabolic risk factors are also seen. The safety profile of
the drug is also acceptable. The most common adverse effects experienced by the patient are gastrointestinal
upsets such as nausea and vomiting.